<DOC>
	<DOCNO>NCT01088178</DOCNO>
	<brief_summary>The investigator study prospective randomize trial woman undergo levonorgestrel intrauterine system ( LNG-IUS : Mirena© , Bayer ) three separate time period : immediate post placental ( IPP ) define insertion within 10 min delivery placenta , early post partum ( EP ) define insertion 10 min within 72hrs postpartum , interval ( INT ) insertion define insertion 6wks postpartum . This pilot study preparation multicenter , prospective randomize study long-acting reversible contraception postpartum period .</brief_summary>
	<brief_title>Levonorgestrel-Intrauterine System ( LNG-IUS ) Insertion Postpartum Period</brief_title>
	<detailed_description />
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>All reproductive age woman express desire LNGIUS ( Mirena© ) routine question 3638 week prenatal appointment upon admission labor delivery eligible study . Contraindications LNGIUS include : Pregnancy suspicion pregnancy , Congenital acquire uterine anomaly include fibroid distort uterine cavity , Postpartum endometritis within past 3 month , Known suspect uterine cervical neoplasia unresolved , abnormal pap smear , untreated acute cervicitis vaginitis include bacterial vaginosis lower genital tract infection , acute liver disease liver tumor , hypersensitivity component product , know suspect carcinoma breast . Any condition would exclude patient study . Delivery &lt; 36 week Intrapartum chorioamnionitis ( defined maternal fever &gt; 100.4 two follow condition : Maternal leukocytosis ( great 15,000 cells/cubic millimeter ) , Maternal tachycardia ( great 100 beats/minute ) , Fetal tachycardia ( great 160 beats/minute ) , Uterine tenderness , Foul odor amniotic fluid Postpartum Hemorrhage ( define &gt; 500cc EBL spontaneous vaginal delivery ) Cesarean delivery randomize IPP EP placement</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Long-Acting Reversible Contraception</keyword>
	<keyword>Contraceptive Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Contraceptive Agents , Female</keyword>
	<keyword>Reproductive Control Agents</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Levonorgestrel</keyword>
</DOC>